UNSPSC 51402308: Enpiprazole hydrochloride

This classification denotes an anxiolytic C16H21ClN4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9R6Z7M2000, chemically known as piperazine, 1-(2-chlorophenyl)-4-(2-(1-methyl-1h-pyrazol-4-yl)ethyl)-, hydrochloride (1:2), but more generally known as enpiprazole hydrochloride, which bears US NIH Compound Identifier 71586941. European Medicines Agency schedules Enpiprazole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01892MIG.

Most nations, for tariff and trade purposes, schedule enpiprazole hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ENPIPRAZOLE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC(CN1)CCN2CCN(CC2)C3CCCCC3CL.CL.CL.

UNSPSC 51402308 Enpiprazole hydrochloride, a Commodity code, represents a specific pharmaceutical ingredient that does not align with the state and local procurement activity currently tagged under this code. The recent solicitations posted under 51402308 involve naloxone, safe drug deactivation systems, direct-to-manufacturer pharmacy benefit programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are enpiprazole hydrochloride or chemically related compounds. The code appears to show a classification mismatch rather than active procurement demand for enpiprazole hydrochloride at the state and local level.

The tagged opportunities reflect activity by state health agencies (Texas Health and Human Services Commission), county public health departments (Seminole County, Florida), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The most recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), Texas HHS's RFI on direct-to-manufacturer prescription programs (due April 3, 2026), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). These procurements target pharmaceutical distribution and benefit-program infrastructure rather than a single active pharmaceutical ingredient. No recent state and local procurement activity specific to enpiprazole hydrochloride is evident in the available records.